Corvus director granted 15,000 stock options

Corvus Pharmaceuticals director Linda Grais received a grant of stock options as equity compensation.

Rhea-AI Filing Summary

Corvus Pharmaceuticals director Linda Grais received a grant of stock options as equity compensation. The Form 4 shows an award of 15,000 options to buy Common Stock at an exercise price of $11.6000 per share, expiring on June 11, 2036.

The underlying 15,000 shares vest and become exercisable 100% on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of stockholders, assuming she continues to serve as a director through that vesting date.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Grais Linda

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	15,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 15,000 contracts (Direct)

Footnotes (1)

1. F1. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Key Figures

Stock options granted: 15,000 options Exercise price: $11.6000 per share Underlying shares: 15,000 shares +2 more

5 metrics

Stock options granted 15,000 options Grant to director Linda Grais on June 11, 2026

Exercise price $11.6000 per share Stock Option (Right to Buy) for Common Stock

Underlying shares 15,000 shares Common Stock underlying the option grant

Total options after grant 15,000 options Total derivative securities owned following this transaction

Option expiration date June 11, 2036 Expiration of Stock Option (Right to Buy)

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, Annual Meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 11.6000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares"

Annual Meeting of the Issuer's stockholders financial

"on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Corvus Pharmaceuticals (CRVS) disclose in this Form 4 for Linda Grais?

Corvus Pharmaceuticals reported that director Linda Grais received a grant of 15,000 stock options. These options give her the right to buy Common Stock at a set price, reflecting standard equity-based director compensation rather than an open-market share purchase or sale.

How many Corvus Pharmaceuticals stock options were granted to Linda Grais and at what price?

Linda Grais was granted 15,000 stock options with an exercise price of $11.6000 per share. This means she can buy up to 15,000 shares of Common Stock at that fixed price once the options vest and are exercisable.

When do Linda Grais’s Corvus Pharmaceuticals stock options vest and become exercisable?

The options vest and become exercisable as to 100% of the 15,000 underlying shares on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting. Vesting requires her continuous service as a director through that date.

When do the Corvus Pharmaceuticals stock options granted to Linda Grais expire?

The stock options granted to Linda Grais expire on June 11, 2036. After that expiration date, any unexercised options will lapse, and she will no longer have the right to purchase Common Stock at the $11.6000 exercise price.

Is Linda Grais’s Form 4 transaction a market purchase or sale of Corvus Pharmaceuticals shares?

The Form 4 reflects a grant of stock options, not a market purchase or sale of shares. It is categorized as a grant, award, or other acquisition, providing potential future share ownership rather than an immediate open-market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grais Linda

(Last) (First) (Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.6	06/11/2026		A		15,000		(1)	06/11/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

	/s/ Leiv Lea, as Attorney-in-Fact for Linda S. Grais	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)